Sei Investments Co. Sells 106,987 Shares of Eli Lilly and Company $LLY

Sei Investments Co. trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 16.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 562,345 shares of the company’s stock after selling 106,987 shares during the quarter. Sei Investments Co. owned about 0.06% of Eli Lilly and Company worth $429,076,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of LLY. Laurel Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $8,827,714,000. Capital Research Global Investors grew its stake in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in Eli Lilly and Company by 47.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock valued at $1,761,772,000 after buying an additional 744,868 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Medicare access is expanding for Zepbound and Mounjaro, which should boost near‑term demand and reduce payer uncertainty for a large patient cohort. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Lilly announced a multibillion manufacturing build‑out in China to secure supply and capture a huge GLP‑1 market — a strategic long‑term revenue driver. Lilly to Invest $3 Billion in China to Boost Obesity Pill
• Positive Sentiment: Lilly is expanding manufacturing and partnerships in Asia (Korea $500M incubator and Japan plant expansion), diversifying capacity and helping global rollout. Eli Lilly invests $500 million in Korea’s biotech growth
• Positive Sentiment: Lilly is pushing multiple product catalysts: an orforglipron filing/launch (oral GLP‑1) and follow‑on candidates (retatrutide) that can sustain growth beyond current injectables. Will Policy Shifts Accelerate Demand for Eli Lilly’s GLP‑1 Drugs?
• Positive Sentiment: Employer Connect and LillyDirect initiatives aim to expand coverage and patient access (potential volume growth even if pricing is pressured). Lilly Employer Connect platform launch
• Neutral Sentiment: Premium share price and 5‑year outperformance have reignited stock‑split and megatrend commentary — sentiment boosters but not immediate fundamentals. Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years (LLY)
• Negative Sentiment: Lilly issued warnings after detecting an unknown impurity in compounded tirzepatide mixed with vitamin B12 — a safety/regulatory concern that can drive near‑term caution and compounding‑market scrutiny. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Shorter‑term technical/market‑sentiment concerns: some analysts/public pieces argue trading momentum has cooled since late 2025, which can accelerate sell‑offs after recent gains. Eli Lilly Reaching For Peak GLP‑1 Euphoria: Rotten Trading Momentum Since November
• Negative Sentiment: Lilly warned some Medicare plans or basic Part D designs might still leave patients with >$50 out‑of‑pocket costs under new CMS rules — a potential near‑term headwind to access and PR. Lilly Warns Some Medicare GLP‑1 Costs Could Exceed $50

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. HSBC reiterated a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 6th. Argus upped their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Stock Down 2.2%

LLY stock opened at $977.47 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The business has a fifty day moving average price of $1,039.17 and a 200-day moving average price of $947.29. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock has a market capitalization of $923.54 billion, a P/E ratio of 42.59, a P/E/G ratio of 1.16 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the prior year, the company posted $5.32 earnings per share. The company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.